TiborJozsefKovacsovicsMD

PubMed

• 1 citations
  Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
  Fieke W Hoff, William G Blum, Ying Huang, Rina Li Welkie, Ronan T Swords
  Blood Advances. 2024-10-22
• 3 citations
  Menin Inhibition With Revumenib for-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
  Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, John DiPersio, Martha Arellano
  Journal of Clinical Oncology. 2024-08-09
• 7 citations
  A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
  Sheng F Cai, Ying Huang, Jennie R Lance, Hsiaoyin Charlene Mao, Andrew J Dunbar
  Blood Advances. 2024-01-23

Journal Articles

• A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML  
  Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

• A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Mye...
  Tibor Kovacsovics, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
  Tibor Kovacsovics, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML). 
  2019 ASCO Annual Meeting - 6/1/2019